Tetntative Program

ACTC 2014 TENTATIVE PROGRAM


Day 1

Day 2

Day 3

Day 4



DAY 2: Thursday, October 9

Time Session/Title Confirmed Speaker
Thursday, October 9
8:30 – 12:00
Plenary Lecture Session 3:
CTCs as tumor biomarkers in breast cancer
8:30 – 9:00
PL3-1
Characterization of CTCs for optimization of palliative treatment in metastatic cancer Tanja Fehm,Professor, Department of Gynecology, University of Dusseldorf, Germany.
9:00 – 9:30
PL3-2
Liquid Biopsy to interrogate intratumor heterogeneity in breast cancer: dream or reality Michail Ignatiadis, Ass. Professor, Jules Bordet Institute, Brussels, Belgium
9:30 – 10:00
PL3-3
CTC in breast cancer 2004-2014: clinical value revisited Massimo Cristofanilli, MD, FACP, Appointed Director of the Jefferson Breast Care Center, Kimmel Cancer Center, Philadelphia, PA, USA
10:00 – 10:30
PL3-4
DTC detection and characterisation as a tool for clinical intervention. Bjorn Naume, Professor, Oslo University Hospital, Oslo, Norway
10:30 – 11:00

Networking Coffee Break in the Exhibition Hall

11:00 – 11:30
PL3-5
Clinical validity of CTC for the management of metastatic and locally advanced breast cancer Jean-Yves Pierga, MD, PhD, Professor of Medical Oncology, at the Institute Curie and University Paris Descartes, Paris, France
11:30 – 12:00
PL3-6
CTCs and breast cancer dormancy Sofia Agelaki,
MD, Ass. Professor, Medical School, University of Crete, Greece
12:00 – 13:00 Lunch Break - Exhibition visit
13:00 – 14:00 ORAL PRESENTATIONS Session 2:
(Oral Presentations, Speakers to be selected from submitted abstracts)
Ο2-1
Ο2-2
Ο2-3
Ο2-4
Ο2-5
Ο2-6
Ο2-7
Ο2-8
Ο2-9

14:30 – 17:30 POSTER SESSION 2: CTCs as tumor biomarkers and networking coffee break in the Exhibition Hall
16:00 – 17:30
Drug Development Forum : "Potential Applications of Circulating Tumour Cells in
Clinical Drug Development"
(Pharmaceutical Companies Sponsored Oral Presentations)
(n=3 Speakers, 30 min each)
16:00 – 16:30
ALERE SPONSORED LECTURE CTC-based assay for androgen receptor splice variants (AR-Vs) predicts treatment resistance to novel hormonal therapies in advanced prostate cancer Emmanuel S Antonarakis, MD, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
16:30 – 17:00
ROCHE SPONSORED LECTURE
17:30 – 17:30
ROCHE SPONSORED LECTURE
17:30 – 18:30 EXPERT PANEL:
CTC and personalized medicine: Future challenges
Moderator: Massimo Cristofanilli
Panelists:Stefanie Jeffrey, Michail Ignatiadis, Dimitris Mavroudis, Bjorn Naume, Jean-Yves Pierga, Sofia Agelaki
19:00 – 22:00
Faculty Dinner